Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Apr 24, 2021; 12(4): 217-237
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.217
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender, Department of Oncology, University Hospital Geneva, Geneva 1205, Switzerland
Alex Friedlaender, Department of Oncology, Clinique Générale Beaulieu, Geneva 1206, Switzerland
Author contributions: Chevallier M and Borgeaud M contributed equally to this work; the concept was from Addeo A and Friedlaender A; all authors participated in drafting, editing the manuscript, read and approve the final manuscript.
Conflict-of-interest statement: Mathieu Chevallier and Maxime Borgeaud declare no potential conflicts of interest; Alfredo Addeo has received compensation from Bristol-Myers Squibb, AstraZeneca, Merck Sharpe & Dohme, Takeda, Pfizer, Roche and Boehringer Ingelheim for participating on advisory boards; Alex Friedlaender has received compensation from Roche, Pfizer, Merck Sharpe & Dohme, and Bristol-Myers Squibb for participating in advisory boards.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alex Friedlaender, MD, Department of Oncology, University Hospital Geneva, 4 rue Gabrielle-Perret Gentil, Geneva 1205, Switzerland. alex.friedlaender@hcuge.ch
Received: January 27, 2021
Peer-review started: January 27, 2021
First decision: March 1, 2021
Revised: March 5, 2021
Accepted: April 7, 2021
Article in press: April 7, 2021
Published online: April 24, 2021
Processing time: 82 Days and 22.6 Hours
Core Tip

Core Tip: We have reviewed the current literature about the impact of detecting oncogenic mutations in non-small cell lung cancer (NSCLC). Over the years, the adoption of next generation sequencing has rendered it easier to determine and detect possible oncogenic driver mutations, leading to the development of several targeted therapies. The clinical impact and benefit for patients is important in terms of quality and quantity of life. These therapies are more effective than standard chemotherapy treatment. We have reviewed the data to explain what has been done, is ongoing and shall be done in the future for patients with oncogene-driven NSCLC.